Search Results for "Rituximab Patent"

10:47 EDT 2nd September 2015 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion files IPR against Genentech

Celltrion Inc. (KOSDAQ:068270) filed an inter partes review (IPR) petition with the U.S. Patent and Trademark Office challenging a patent from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) t...

Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rit...

Complement 3b Deposition on Rituximab Opsonized

The ImageStream® imaging flow cytometry platform was used to study the mechanism of action of Rituximab (RTX). RTX is a therapeutic monoclonal antibody directed against CD20 for the treatment o...

Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome

A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituxim...

Further evidence of Rituximab’s effectiveness in treating ME/CFS | PlosOne publish results of Phase 2 trial | 1 July 2015

Øystein Fluge and Olav Mella – they're leading the Rituximab trials in Norway.

Rituximab Re-Up Strategy Is Drug-Sparing Therapy (CME/CE)

(MedPage Today) -- RESORT demonstrates rituximab restart is just as effective as maintenance strategy.

Rituximab discussion on BBC Radio Cambridgeshire | 22 March 2015

Two Norwegian scientists, Øystein Fluge and Olav Mella, who have been researching the effects of an anti-lymphoma drug called Rituximab on people with ME/CFS, talked about their work on the...

Rituximab Safe for Up to 11 Years in Rheumatoid Arthritis

An analysis of data for nearly 3000 patients with RA treated with rituximab for up to 11 years showed no increased risk for serious infection cardiac events or malignancy. Medscape Medical News

Matching PubMed Articles

Patent Deployment Strategies and Patent Value in LED Industry.

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields ...

Patent Highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis.

To the Editor: In their article on the Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trial, Guillevin and colleagues (Nov. 6 issue)(1) report that rituxi...

Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis.

To the Editor: In their article on the Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trial, Guillevin and colleagues (Nov. 6 issue)(1) report that rituxi...

Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis.

To the Editor: In their article on the Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trial, Guillevin and colleagues (Nov. 6 issue)(1) report that rituxi...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement